Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305334 | 0.86 | LMNA (0.53) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL329399 | 0.82 | MAPT (0.46) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL31665885 | 0.82 | MAPT (0.46) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL3136339 | 0.82 | MAPT (0.46) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL544259 | 0.82 | MAPT (0.46) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL2244849 | 0.79 | LMNA (0.50) | MAPTNPC1RAB9ALMNAGAA | |
| Formamide SCHEMBL9380540 | 0.79 | LMNA (0.47) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL15157903 | 0.78 | MAPT (0.46) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL14862829 | 0.78 | MAPT (0.47) | MAPTNPC1RAB9ALMNAGAA | |
| SCHEMBL8232118 | 0.78 | MAPT (0.47) | MAPTNPC1RAB9ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117835980-A | Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof | 朗多生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4225315-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | Nimmune Biopharma, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4196475-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-21 | — | — | EP | disclosed |
| US-7956082-B2 | Indole derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA | 2011-02-03 | — | — | US | disclosed |
| US-7842692-B2 | Azaindole derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | SHIONOGI & CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1939175-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi&Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1932839-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1916245-A1 | INDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1911759-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, HRH2, PTGDR2 | MAPT 4862/4885NPC1 3292/4885RAB9A 2727/4885 |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, CYSLTR1, CNR1 | MAPT 4844/4885NPC1 3625/4885RAB9A 3551/4885 |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, HRH2, PTGDR2 | MAPT 4869/4885NPC1 3377/4885RAB9A 3393/4885 |
| US-20230192652-A1 | PLXDC2 LIGANDS | PLP2, PDCD1LG2, LCP2 | MAPT 300/4885NPC1 3791/4885RAB9A 2749/4885 |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | HRH2, PTGDR, CNR2 | MAPT 4656/4885NPC1 2365/4885RAB9A 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.